Report me for selling fake medicine? Why are you crying when your illness relapses?

He also expressed this very clearly.

But at the same time, this also means to remind Gao Tianlong that if the price is not high enough, don't waste time.

"Mr. Chen, don't worry about the price. Our offer will definitely satisfy you."

"Twenty billion. We at AbbVie plan to spend twenty billion to acquire the complete formula."

"From now on, the global intellectual property rights of this drug will belong to AbbVie, which is equivalent to a one-time buyout."

"Mr. Chen, we are very sincere in cooperating with you, so our offer is also very sincere."

Gao Tianlong said confidently that he believed this price was enough to impress Chen Xuan.

After all, 200 billion for one drug formula.

Whether this can be considered unprecedented is hard to say.

But a drug formula that has not yet completed clinical trials can be sold for 200 billion. This is the first time in history.

Therefore, he was confident that he could impress Chen Xuan, and the latter would definitely agree to this condition.

AbbVie originally did not intend to bid 200 billion at once, as they believed that clinical trials still had certain risks.

But after Changfeng Group made its bid, AbbVie immediately changed its mind, and Gao Tianlong's reserve price was much higher.

This move is worth 200 billion, and a big reason for this is the influence brought by Changfeng Group.

"Besides, if Mr. Chen is willing,"

"We can also acquire 60% of Antai Pharmaceutical Group's shares for 120 billion yuan."

"We at AbbVie are very interested in both you and Antai Pharmaceutical Group, and hope to maintain long-term cooperation with you. With AbbVie's support, you will surely achieve even greater success in drug development."

Before Chen Xuan started, Gao Tianlong spoke again.

It sounds like AbbVie only spent 120 billion to acquire shares, which seems to be no different from Changfeng Group.

But the difference is that Changfeng Group's 120 billion yuan directly includes the formula of the special medicine for lung cancer, which is why the total valuation is 120 billion yuan.

AbbVie's 120 billion yuan was for the acquisition of additional shares after acquiring the new drug formula. It seems the same, but there is a huge difference between the before and after.

The difference is that Changfeng Group's plan allows Chen Xuan to retain 40% of the new drug patents, while Abovie's acquisition plan means that the new drug has nothing to do with him, but he can directly get an additional 20 billion yuan in cash.

In total, they could have earned 320 billion yuan, but the price they paid was losing the patent for the new drug and 60% of the group's shares.

Relatively speaking, AbbVie's bid is very generous, a real big deal.

"I feel your company's sincerity, and the conditions are indeed good."

"But... I'm sorry, I really don't intend to sell the formula."

Chen Xuan refused bluntly.

He will not sell the formula for the lung cancer drug, nor will he sell his shares in Antai Pharmaceutical Group.

Once he sells 60% of his shares, Antai Pharmaceutical Group will no longer belong to him.

According to the usual practice of foreign companies, all the advantages of Chinese companies will be eliminated, and finally they will become empty shells and destroy a brand directly.

This is especially true for corporate acquisitions within the same industry. Few Chinese brands can continue to perform better after being acquired, and most of them decline rapidly after being acquired.

They would rather lose money than suppress China's development.

The same goes for Antai Pharmaceutical Group. After being acquired by Abovie, it will definitely not develop with all its heart. Instead, Antai Pharmaceutical Group will continue to transfer profits to Abovie, and eventually be sucked dry.

So, how could Chen Xuan possibly sell his shares, let alone sell 60% at once?

Once he loses his status as a major shareholder, the future development of Antai Pharmaceutical Group will no longer be in his hands.

Moreover, there is a high possibility that he will be kidnapped by the Antai Group, and in the end he will have no choice but to work for AbbVie and contribute to it, and lose his freedom.